Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 5% less
These brands contain the same active ingredient (Terbinafine Hydrochloride). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Mycocure is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Terbinafine tablet: For treating fingernail onychomycosis, the usual dose is Terbinafine 250 mg (one tablet) once daily for 6 weeks. For treating toenail onychomycosis, the usual dose is Terbinafine 250 mg (one tablet) once daily for 12 weeks. The best clinical effect is seen some months after mycological cure and stopping treatment, since this is related to the time needed for a healthy nail to grow out. Terbinafine granules: For body weight under 25 kg, the dose is 125 mg per day for up to 6 weeks. For body weight between 25 and 35 kg, the dose is 187.5 mg per day for up to 6 weeks. For body weight over 35 kg, the dose is 250 mg per day for up to 6 weeks. Terbinafine cream: The cream can be applied once or twice daily. Cleanse and dry the affected areas thoroughly before applying it. Apply the cream to the affected skin and the surrounding area in a thin layer and rub it in lightly. For intertriginous infections (submammary, interdigital, intergluteal, inguinal), the application may be covered with a gauze strip, especially at night. Likely treatment durations are as follows. Tinea corporis and cruris usually need 1 to 2 weeks. Tinea pedis usually needs 1 week. Cutaneous candidiasis usually needs 2 weeks. Pityriasis versicolor usually needs 2 weeks. Relief of clinical symptoms usually occurs within a few days. Irregular use or stopping treatment too early carries a risk of recurrence. If there are no signs of improvement after two weeks, the diagnosis should be verified. Terbinafine 1% Spray: This spray is applied once or twice daily, depending on the indication. The affected areas should be cleansed and dried thoroughly before applying the spray, using enough solution to wet the treatment area or areas thoroughly. For tinea pedis, apply once a day for 1 week. For tinea corporis or cruris, apply once a day for 1 week. For pityriasis versicolor, apply twice a day for 1 week. Relief of clinical symptoms usually occurs within a few days. If there are no signs of improvement after two weeks, the diagnosis should be verified.
Side Effects
Reported side effects include gastrointestinal symptoms such as diarrhea, indigestion, and abdominal pain, along with liver test abnormalities, skin rashes, hives, itching, and changes in taste. These effects are usually mild and temporary and generally do not require the medicine to be stopped. Based on worldwide experience with terbinafine, other reported effects include idiosyncratic and symptomatic liver injury and, more rarely, liver failure, which in some cases has led to death or the need for a liver transplant; serious skin reactions; a marked drop in certain white blood cells or platelets; swelling beneath the skin (angioedema); and allergic reactions, including anaphylaxis. Additional reported effects include malaise, fatigue, vomiting, joint pain, muscle pain, and hair loss.
Cautions & Contraindications
Warnings & Precautions
Warnings for Terbitac tablets: Rare cases of liver failure, some leading to death or liver transplant, have occurred with the use of terbinafine tablets for the treatment of onychomycosis in individuals with and without preexisting liver disease. In most of the reported liver cases associated with terbinafine use, the patients had serious underlying systemic conditions, and the causal link with terbinafine was uncertain. The severity of hepatic events and their outcome may be worse in patients with active or chronic liver disease. Treatment with terbinafine tablets should be discontinued if there is biochemical or clinical evidence of liver injury. There have been isolated reports of serious skin reactions (such as Stevens-Johnson Syndrome and toxic epidermal necrolysis). If progressive skin rash occurs, treatment with terbinafine should be discontinued. Terbitac cream is for external use only, and contact with the eyes should be avoided. Precautions: Terbitac is not recommended for patients with chronic or active liver disease. Before prescribing Terbitac, pre-existing liver disease should be assessed, since hepatotoxicity may occur in patients with or without such a history. Pretreatment serum transaminase (ALT and AST) tests are advised for all patients before starting terbinafine tablets.
Contraindications
Terbinafine hydrochloride tablets and cream should not be used by anyone who is hypersensitive to terbinafine.